The other patient had stage 4 disease with ovarian metastasis (adenocarcinoma histology, PD-L1 CPS 5, TMB 6.3 mut/Mb, TP53 mutation, CCNE1 and ERBB2 amplification, and HER3 3+). Here, ERBB2 is linked to adenocarcinoma.